Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Welsh Carson Taps Into Spinal Market with K2M Buy

This article was originally published in Start Up

Executive Summary

Welsh, Carson, Anderson & Stowe, a long time investor in health care services companies, signaled its intent to invest more deeply in the device sector with the acquisition of a majority position in spinal company K2M Inc.

You may also be interested in...

Welsh Carson Sits in K2M Driver's Seat

With the backing of the private equity powerhouse Welsh Carson, K2M will look to grow beyond its historical niche in complex spinal cases, though it will have to do so without any financial ties to the surgeons who once owned part of the company.

Orthopedics Settlement: Puts the Issue to Bed--Or Does It?

Though government officials and critics in the press painted lucrative consulting arrangements as unscrupulous tools in the hands of Big Ortho, no one's happier to see them go than the orthopedics industry itself. Here’s how the details shake out for the industry, and why executives are actually relieved to have some sticky legal and moral issues disappear. Some even predict that the end result will be lower overhead for their companies.

InnerPulse: Bringing the Interventional Revolution to CRM

By employing catheter-based technology, a rare cardiac rhythm management start-up is looking to enable more physicians to treat arrhythmias to increase the patient pool and grow the overall electrophysiology device market.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts